One month after shares of Anthera Pharmaceuticals Inc. (NASDAQ:ANTH) took a 30 percent haircut following a phase III miss by blisibimod in the lead indication of systemic lupus erythematosus (SLE), investors did an about-face on maturing data from the phase BRIGHT-SC proof-of-concept study of the same agent in individuals with IgA nephropathy (IgAN), also known as Berger's disease.